Trifarotene Aklief denied as non-formulary by Aetna?

Aetna's specific coverage criteria for trifarotene aklief are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Trifarotene (Aklief) as Non-Formulary

Aklief (trifarotene) is a branded topical retinoid. Aetna's formulary tiers generally give preferred placement to lower-cost generic retinoids — tretinoin and adapalene are the most common. Trifarotene, as a newer branded agent without a generic equivalent, is frequently placed in a non-preferred or non-formulary tier, resulting in either a higher cost-share or an outright coverage denial depending on your specific plan design. A non-formulary denial does not mean the drug is clinically inappropriate — it means the plan wants documentation that formulary alternatives have been tried and failed or are unsuitable.

## Why a Non-Formulary Denial Is Appealable

All plan formularies must include an exceptions process. Aetna is required to grant a formulary exception when a formulary alternative would be clinically inferior for your specific situation, when you have already tried and failed formulary alternatives, or when a formulary alternative is medically contraindicated. A well-documented exceptions request is the primary tool for accessing non-formulary drugs at the preferred cost-share.

## Your Federal Appeal Rights

• Formulary exception request: This is often the fastest path — file this before or alongside the formal appeal. Aetna must respond within the standard or expedited regulatory timeline.
• Internal appeal: If the exception is denied, file a formal internal appeal with full clinical documentation.
• External review (ACA §2719): After internal appeal exhaustion, request independent external review — typically within about four months of the original denial. The IRO is not bound by Aetna's formulary decisions.
• ERISA §503: Employer-plan members may obtain all plan documents and criteria used in the formulary determination.

## Documentation to Gather

• Formulary alternatives tried: Document every formulary retinoid previously used — tretinoin, adapalene, or other covered alternatives — with dates, adherence, and specific outcomes (inadequate response, skin irritation requiring discontinuation, etc.).
• Prescriber letter: Your dermatologist should explain why trifarotene provides a clinically meaningful benefit not achievable with the formulary alternatives, referencing the FDA label's specific approval characteristics.
• Chart notes: Current severity documentation and visit notes supporting the treatment decision.
• Aetna's formulary exception criteria: Request the exact criteria so your letter addresses each element directly.

## Criteria-Mapping Structure

| Formulary Exception Criterion | Your Evidence | |---|---| | Formulary alternative tried | Medication record showing [formulary retinoid], dates, outcome | | Alternative inadequate or not tolerated | Chart note documenting [specific outcome] | | Medical need for non-formulary drug | Prescriber letter explaining clinical distinction |

Pairing the formulary exception request with the formal appeal simultaneously is the most efficient strategy — it preserves your appeal rights while giving Aetna the opportunity to resolve the issue administratively without reaching external review.